Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Type 2 Diabetes (T2D) Market Report Overview
The T2D market value for the 9 markets (9MM) was $45.9 billion in 2019. T2D is a chronic disease characterized by insulin resistance and pancreatic β-cell failure, as defined by the International Classification of Diseases 11th edition (ICD-11), with an underlying genetic predisposition heavily influenced by diet and lifestyle. This disease is a multi-causal, heterogeneous, and progressive cardiometabolic condition that is commonly associated with obesity, dyslipidemia, hypertension, inflammation, and endothelial dysfunction. The prevalence of diabetes is expected to grow rapidly, as it is associated with aging populations, increasing urbanization, economic development, and the increase in the prevalence of risk factors like obesity, unhealthy dietary habits, and physical inactivity.
The T2D market research report provides an analysis of the key dynamics of the T2D market. The report also offers insights into the key industry drivers and challenges. It also covers deals and R&D strategies in detail to highlight potential business opportunities.
T2D Market Drivers
The most important driver of growth in the T2D marketplace will be a dramatic increase in the prevalence and diagnosis of the disease. The rise in T2D-related comorbidities has fueled the more aggressive approach to the treatment and the use of multiple-drug therapies.
The obesity epidemic in the US will fuel the number of T2D patients. The main shift in the position of the ADA guidelines, reflected in a more personalized and patient-tailored approach, will drive the market for many me-too therapies in the T2D space. Diabetes screening programs for high-risk patients could increase the patient pool. Increasing rates of obesity and heart disease lead to a likely increase in the incidence of Type 2 Diabetes, further driven by the ageing population in the EU.
To know more about the drivers of the T2D market, download a free report sample
T2D Market Unmet Needs
Several newly marketed and late-stage pipeline products are positioned to somewhat address the unmet needs in the treatment of T2D. New insulin formulations are also emerging, but they only offer a modest increase in overall efficacy and safety. Overall, the majority of unmet needs in T2D will remain unfulfilled for the foreseeable future. Patients still lack an effective antidiabetic treatment that can be used in all phases of the chronic disease, leaving a significant growth opportunity for new patented products that can meet these needs.
To know more about the unmet needs in the T2D market, download a free report sample
T2D Market Segmentation by Regions
The key regions in the T2D market are the US, 5EU (France, Germany, Italy, Spain, and the UK), and APAC (China, India, and Japan). The US had the highest share in 2019, followed by APAC, and 5EU respectively.
T2D Market Analysis by Regions
For more regional insights on the T2D market, download a free report sample
T2D Market - Competitive Landscape
Some of the leading players in the T2D market are Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others. Takeda is the leading sponsor of cell therapy trials in T2D.
T2D Market Analysis by Companies
For more insights on companies in the T2D market, download a free report sample
T2D Market Report Overview
| Market Size (2019 in 9MM) | $45.9 billion |
| Key Regions | The US, 5EU (France, Germany, Italy, Spain, and the UK), and APAC (China, India, and Japan) |
| Leading Players | Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others |
Scope
- The proportion of people at risk of developing T2D is expected to increase over the 10-year forecast period due to an increased life expectancy coupled with rapid socioeconomic change, increased prevalence of obesity and the increased prevalence of cardiovascular (CV) disease
- The potential launch of 10 late-stage pipeline agents will increase the number of patients who can be offered pharmacological treatment options. In addition, five of these drugs in late-stage development are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
- Cardiorenal disease is being increasingly recognized in clinical practice and there has been a renewed interest among the medical community to understand the pathophysiological mechanisms underpinning its pathogenesis.
- Despite the plethora of therapies currently available to T2D patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for patients unable to achieve optimal glycemic control.
Reasons to Buy
The report will help to understand:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global type 2 diabetes market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global type 2 diabetes therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The T2D market value for the 9MM was $45.9 billion in 2019.Some of the leading players in the T2D market are Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others.
The key regions in the T2D market are the US, 5EU (France, Germany, Italy, Spain, and the UK), and APAC (China, India, and Japan).
The US has the highest share in the T2D market.
Some of the leading players in the T2D market are Takeda, GSK, AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly, Merck, and others.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.